Haduvio (oral nalbuphine ER)
Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)
Key Facts
About Trevi Therapeutics
Trevi Therapeutics is a clinical-stage biotech company with a focused mission to address the debilitating burden of chronic cough through its proprietary KAMA mechanism platform. Its key achievement in 2025 was announcing positive Phase 2b (CORAL) and Phase 2a (RIVER) trial results for Haduvio in IPF and RCC, respectively, positioning it as a potential first-to-market therapy. The company's strategy is to rapidly advance Haduvio through late-stage development and regulatory approval in these multi-billion-dollar, untapped markets. Trevi's $1.45B valuation reflects significant investor confidence in its clinical progress and commercial potential.
View full company profileAbout Trevi Therapeutics
Trevi Therapeutics is a clinical-stage biotech company with a focused mission to address the debilitating burden of chronic cough through its proprietary KAMA mechanism platform. Its key achievement in 2025 was announcing positive Phase 2b (CORAL) and Phase 2a (RIVER) trial results for Haduvio in IPF and RCC, respectively, positioning it as a potential first-to-market therapy. The company's strategy is to rapidly advance Haduvio through late-stage development and regulatory approval in these multi-billion-dollar, untapped markets. Trevi's $1.45B valuation reflects significant investor confidence in its clinical progress and commercial potential.
View full company profileAbout Trevi Therapeutics
Trevi Therapeutics is a clinical-stage biotech company with a focused mission to address the debilitating burden of chronic cough through its proprietary KAMA mechanism platform. Its key achievement in 2025 was announcing positive Phase 2b (CORAL) and Phase 2a (RIVER) trial results for Haduvio in IPF and RCC, respectively, positioning it as a potential first-to-market therapy. The company's strategy is to rapidly advance Haduvio through late-stage development and regulatory approval in these multi-billion-dollar, untapped markets. Trevi's $1.45B valuation reflects significant investor confidence in its clinical progress and commercial potential.
View full company profileTherapeutic Areas
Other Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF) Drugs
| Drug | Company | Phase |
|---|---|---|
| ME-015 (Suplatast Tosilate) | Melius Pharma | Phase 2 |